

INVITED
COMMENTARY

Targeting the HPA axis in major depression: does it work?

INVITED COMMENTARY ON... ANTIGLUCOCORTICOIDS IN PSYCHIATRY[†]

Stephan Claes

Stephan Claes is Professor of Psychiatry at the Catholic University of Leuven, Belgium. He is also a senior clinical investigator of the Fund for Scientific Research – Flanders. His research interests are the function of the HPA axis and its genetic background in psychiatric disorders.

Correspondence Professor Stephan Claes, Department of Psychiatry, University Hospital Leuven, Herestraat 49, 3000 Leuven, Belgium. Email: Stephan.Claes@uzleuven.be

[†]See pp. 242–249, this issue.

SUMMARY

In the search for antidepressant drugs with enhanced efficacy, targeting the hypothalamic–pituitary–adrenal (HPA) axis is a valid strategy. This commentary critically summarises the evidence for the efficacy of antidepressant drugs targeting the HPA axis, and concludes that the available clinical trials do not support claims that this class of drugs is superior to existing treatments.

DECLARATION OF INTEREST

S. C. is or has been member of the Belgian Advisory Board of Eli Lilly, Wyeth, BMS, Servier, and Lundbeck. He has received a research grant from Johnson & Johnson.

HPA axis is compelling. But will such drugs be more efficient than our current treatments? A critical review of the literature calls for modesty.

Antiglucocorticoid drugs

Compounds that have been studied include ketoconazole, metyrapone, aminoglutethimide, dehydroepiandrosterone (DHEA) and glucocorticoid receptor agonists or antagonists. Very recently, the Cochrane collaboration published an extensive review on available trials with these drugs (Gallagher 2008). The overall examination of the eight available trials (totalling 211 patients) was not able to show significant differences in treatment response to antiglucocorticoids compared with placebo. Looking at the trials separately, however, some interesting results are reported. A randomised controlled trial (RCT) involving 63 individuals with major depressive disorder (Jahn 2004) showed that adding metyrapone to standard antidepressants induced a more rapid, more efficacious and sustained treatment response. This trial awaits confirmation.

A stronger case could be made for DHEA. A small RCT involving 22 people with major depressive disorder (Wolkowitz 1999) reported that DHEA is an effective antidepressant. This was confirmed more recently in a larger RCT (Schmidt 2005) in midlife-onset major and minor depression, and in a controlled study involving people with HIV and subsyndromal depressive disorder (Rabkin 2006). However, it is most uncertain that the antidepressant properties of DHEA are HPA-axis related. Dehydroepiandrosterone and its metabolite DHEA-S exert numerous functions: acting as a precursor to testosterone and oestradiol, each of which independently has been associated with mood effects; modulation of multiple neurotransmitter systems (Pérez-Neri 2008); regulation of pro-inflammatory cytokines such as tumour necrosis factor alpha and interleukin-6, which have been shown to be involved in major depressive disorder (Lanquillon, 2000); and

The current pharmacological treatment of major depressive disorder is far from perfect. In recent meta-analyses, the overall effect size of antidepressant drug treatment was estimated at 0.31 (Turner 2008). Some authors even conclude that there are no good grounds to prescribe antidepressant drugs to any but the most severely depressed patients (Kirsch 2008). Part of this limited efficacy is undoubtedly due to the complexity of major depressive disorder itself. What DSM-IV (American Psychiatric Association 1994) calls major depressive disorder is probably a mixture of syndromes which are very different not only in clinical appearance but also in neurobiological background, making it impossible for any drug to be effective in the majority of people with major depressive disorder. Another explanation is that we are urgently in need of drugs that tackle more directly the core neurobiological dysfunctions in major depressive disorder. The article by McIsaac and colleagues on antiglucocorticoids in psychiatry offers an excellent example of the search for such drugs (McIsaac, pp. 242–249, this issue). They convincingly review the literature that situates HPA axis dysregulation at the core of the neurobiology of major depressive disorder. The logic of developing antidepressant drugs that directly target the

exerting antiglucocorticoid properties, as long-term exposure to DHEA affects the transcriptional activity of the glucocorticoid receptor (Saponaro 2007).

Mifepristone (RU-486) blocks progesterone and, at higher doses, cortisol receptors. A few RCTs have studied the drug for psychotic major depressive disorder (DeBattista 2006; Flores 2006). They indicate the efficacy of RU-486 in reducing psychotic symptoms at the beginning of treatment, but showed no significant effect on mood symptoms. An RCT involving people with bipolar disorder equally demonstrated no significant difference in mood symptoms between patients treated with RU-486 and those receiving placebo (Young 2004).

CRH receptor antagonists

As hypersecretion of corticotropin-releasing hormone (CRH) is thought to be at the core of major depressive disorder neurobiology, antagonising the CRH type 1 (CRH₁) receptor at the level of the pituitary seems the logical thing to do. An early uncontrolled study was promising (Zobel 2000), and several RCTs are currently underway. One recent RCT compared the efficacy of a CRH₁ receptor antagonist (CP-316,311), sertraline and placebo in the treatment of 123 people with major depressive disorder (Binneman 2008). The trial was terminated after a preliminary analysis on 30 patients in each group showed no evidence for the efficacy of CP-316,311. It is interesting to notice that sertraline showed an effect that was larger than that of the SSRIs in the meta-analysis by Kirsch (2008). The results of other such trials have to be awaited.

Taken together, there is no evidence that drugs targeting the HPA axis will work in the treatment of major depressive disorder, let alone work better than the current generation of antidepressants. One problem may be that the primary cause of HPA-axis dysregulation in major depressive disorder remains unclear. *In vitro* studies indicate a hypofunction of the glucocorticoid receptor as the primary mechanism (Carvalho 2008), in which case glucocorticoid receptor agonists might be more appropriate than antagonists. Furthermore, it is important to realise that current antidepressant treatments targeting monoamine systems already exert important effects on HPA-axis function, as shown by *in vitro*, animal and human studies (Mason 2006). At this stage, the most realistic hope is that drugs such as DHEA, metyrapone and RU-486 will have an added value as (add-on) treatments for specific subgroups with major depressive disorder. This will have to be examined further, as

will alternative targets within the HPA axis, such as the arginine vasopressin receptor 1B.

References

- American Psychiatric Association (1994) *Diagnostic and Statistical Manual of Mental Disorders (4th edn) (DSM-IV)*. APA.
- Binneman B, Feltner D, Kolluri S, et al (2008) A 6-week randomized, placebo-controlled trial of CP-316,311 (a selective CRH1 antagonist) in the treatment of major depression. *American Journal of Psychiatry*, **165**: 617–20.
- DeBattista C, Belanoff J, Glass S, et al (2006) Mifepristone versus placebo in the treatment of psychosis in patients with psychotic major depression. *Biological Psychiatry*, **60**: 1343–9.
- Carvalho LA, Jurueña MF, Papadopoulos AS, et al (2008) Clomipramine *in vitro* reduces glucocorticoid receptor function in healthy subjects but not in patients with major depression. *Neuropsychopharmacology*, **33**: 3182–9.
- Flores BH, Kenna H, Keller J, et al (2006) Clinical and biological effects of mifepristone treatment for psychotic depression. *Neuropsychopharmacology*, **31**: 628–36.
- Gallagher P, Malik N, Newham J, et al (2008) Antigluco-corticoid treatments for mood disorders. *Cochrane Database of Systematic Reviews*, issue 1: CD005168.
- Jahn H, Schick M, Kiefer F, et al (2004) Metyrapone as additive treatment in major depression: a double-blind and placebo-controlled trial. *Archives of General Psychiatry*, **61**: 1235–44.
- Kirsch I, Deacon BJ, Huedo-Medina TB, et al (2008) Initial severity and antidepressant benefits: a meta-analysis of data submitted to the Food and Drug Administration. *PLoS Medicine*, **5**: e45.
- Lanquillon S, Drieg JC, Bening-Abu-Shach U, et al (2000) Cytokine production and treatment response in major depressive disorder. *Neuropsychopharmacology*, **22**: 370–9.
- Mason BL, Pariante CM (2006) The effects of antidepressants on the hypothalamic–pituitary–adrenal axis. *Drug News and Perspectives*, **19**: 603–8.
- Mclsaac, SA, Westrin A, Young AH (2009) Antigluco-corticoids in psychiatry. *Advances in Psychiatric Treatment*, **15**: 242–249.
- Pérez-Neri I, Montes S, Ojeda-López C, et al (2008) Modulation of neurotransmitter systems by dehydroepiandrosterone and dehydroepiandrosterone sulfate: mechanism of action and relevance to psychiatric disorders. *Progress in Neuropsychopharmacology and Biological Psychiatry*, **32**: 1118–30.
- Rabkin JG, McElhiney MC, Rabkin R, et al (2006) Placebo-controlled trial of dehydroepiandrosterone (DHEA) for treatment of nonmajor depression in patients with HIV/AIDS. *American Journal of Psychiatry*, **163**: 59–66.
- Saponaro S, Guarnieri V, Pescarmona GP, et al (2007) Long-term exposure to dehydroepiandrosterone affects the transcriptional activity of the glucocorticoid receptor. *Journal of Steroid Biochemistry and Molecular Biology*, **103**: 129–36.
- Schmidt PJ, Daly RC, Bloch M, et al (2005) Dehydroepiandrosterone monotherapy in midlife-onset major and minor depression. *Archives of General Psychiatry*, **62**: 154–62.
- Turner EH, Matthews AM, Linardatos E, et al (2008) Selective publication of antidepressant trials and its influence on apparent efficacy. *New England Journal of Medicine*, **358**: 252–60.
- Wolkowitz OM, Reus VI, Keebler A, et al (1999) Double-blind treatment of major depression with dehydroepiandrosterone. *American Journal of Psychiatry*, **156**: 646–9.
- Young AH, Gallagher P, Watson S, et al (2004) Improvements in neurocognitive function and mood following adjunctive treatment with mifepristone (RU-486) in bipolar disorder. *Neuropsychopharmacology*, **29**: 1538–45.
- Zobel AW, Nickel T, Künzel HE, et al (2000) Effects of the high-affinity corticotropin-releasing hormone receptor 1 antagonist R121919 in major depression: the first 20 patients treated. *Journal of Psychiatric Research*, **34**: 171–81.

MCQ answers

1	2	3	4	5
a f	a f	a f	a f	a f
b t	b t	b f	b t	b f
c f	c f	c f	c f	c f
d f	d f	d t	d f	d t

MCQs

1 The overall effect size of current antidepressant drugs is estimated to be:

- a 21%
- b 31%
- c 41%
- d 51%.

2 Metyrapone was found to be effective in the treatment of major depressive disorder:

- a in monotherapy
- b as an add-on treatment
- c both of the above
- d none of the above.

3 Dehydroepiandrosterone exerts an antidepressant effect by:

- a modulating multiple neurotransmitter systems
- b regulating pro-inflammatory cytokines, such as tumour necrosis factor alpha and interleukin-6
- c modulating the transcriptional activity of the glucocorticoid receptor
- d all of the above.

4 Mifepristone, which has been tested in patients with psychotic depression, is efficacious in:

- a improving mood symptoms
- b improving psychotic symptoms
- c both of the above
- d none of the above.

5 Current antidepressant treatments targeting monoamine systems already exert effects on HPA axis function. This has been shown by:

- a *in vitro* studies
- b animal studies
- c human studies
- d all of the above.